RETAIN (Prospective follow-up of a subset of patients from HORIZON study)
Campochiaro et al. 2014
Ranibizumab 0.5 mg (PRN)
49 months
34
2 years:
2 years: −7.2
2 years: 2.6
−0.4 (ETDRS)
3 years: +2.6
3 years: −42.5
3 years: 2.1
4 years: +0.5
4 years: −26.2
4 years: 2.0
(Compared with year 1)
SHORE
Campochiaro et al. 2014
Ranibizumab 0.5 mg PRN
15 months
50
+21 (ETDRS)
−247.8
3.8
Ranibizumab 0.5 mg (7 + PRN)
48
+18.7
−289.9
7.6
COMO
Francesco et al.
Ranibizumab 0.5 mg (6 + PRN)
12 months
~200
N/A
N/A
N/A
Dexamethasone 0.7 mg
~200
N/A
N/A
N/A
Note: only BRVO patients are analyzed in this table. Outcomes are not directly comparable because study design and populations varied from each other. The COMO trial is still undergoing; therefore, there are no results available at this time. BRVO: branch retinal vein occlusion; VEGF: vascular endothelial growth factor; BCVA: best-corrected visual acuity; CMT: central macular thickness; ETDRS: early treatment diabetic retinopathy study; LogMAR: logarithm of the minimum angle of resolution; BERVOLT: bevacizumab for RVO long-term follow-up; BRIGHTER: individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion; VIBRANT: intravitreal aflibercept for macular edema following branch retinal vein occlusion; RELATE: scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion; MARVEL: a randomized, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular edema due to branch retinal vein occlusion; RABAMES: ranibizumab for branch retinal vein occlusion associated macular edema study; BRAVO: the ranibizumab for the treatment of macular edema following branch retinal vein occlusion; HORIZON: ranibizumab for macular edema due to retinal vein occlusions; RETAIN: long-term outcomes in patients with retinal vein occlusion treated with ranibizumab; SHORE: study evaluating dosing regimens for treatment with intravitreal ranibizumab injections in subjects with macular edema following retinal vein occlusion; COMO: comparison of intravitreal dexamethasone implant and ranibizumab for macular edema in BRVO.